中国实用内科杂志2024，Vol.44Issue(4)：302-306,5.DOI:10.19538/j.nk2024040108
阿伐曲泊帕联合环孢素治疗输血依赖非重型再生障碍性贫血研究
Research of Avatrombopag combined with cyclosporine in the treatment of transfusion-dependent non-severe aplastic anemia
摘要
Abstract
Objective To evaluate the efficacy and safety of Avatrombopag treatment combined with Cyclosporin A(CsA)therapy in patients with transfusion-dependent non-Severe aplastic anaemia(TD-NSAA).Methods Prospective registration from October 2020 to October 2023,21 patients with TD-NSAA treated with CsA combined with Avatrombopag.Results The median duration of treatment with Avatrombopag was 7.5(1.0-27.0)months,and eighteen patients(85.71％)obtained trilineage hemalogical response:3 cases of complete treatment response(CR)(14.29％),4 case of good treatment response(GPR)(19.05％)and 11 cases of partial treatment response(PR)(52.38％),3 case of partial no treatment response(NR)(14.29％),9 patients(42.86％)achived transfusion dependent.17 cases(80.90％)and 18 cases(85.71％)achived remission at 6 months and 12 months,the median time to get response was 1.6 months(range 0.1-7.4 months).The white blood cell count(2.21 × 109/L vs.3.82 × 109/L,P=0.029),absolute neutrophil count(0.92×109/L vs.1.96×109/L,P=0.001),platelet count(13× 109/L vs.57× 109/L,P=0.002),and reticulocyte(1.84％vs.2.63％,P=0.011)improved markedly.No Avatrombopag-related grade 2 or higher adverse events occurred during treatment.Conclusion The combination of Avatrombopag and CsA might be an appropriate approach for TD-NSAA with good safety.关键词
再生障碍性贫血/输血依赖/阿伐曲泊帕Key words
aplastic anaemia/transfusion-dependent/Avatrombopag分类
医药卫生引用本文复制引用
张婷,师锦宁,李建勇,徐丹,陈小玉,宫跃敏,张雅文,龙启强,孙京男,贾晋松,何广胜..阿伐曲泊帕联合环孢素治疗输血依赖非重型再生障碍性贫血研究[J].中国实用内科杂志,2024,44(4):302-306,5.基金项目
国家自然科学基金(81900109) （81900109）
南京医科大学附属江宁医院免疫细胞转化研究中心开放课题(JNYYZXKY202214) （JNYYZXKY202214）
南京市江宁区科技惠民计划项目(2023081S) （2023081S）
